Akèy › Kansè ovè › Kalifòni › Mountain View
Etid klinik pou Kansè ovè nan Mountain View, CA
19 etid pou Kansè ovè ap chèche patisipan nan sit nan ak bò kote Mountain View (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
Ap rekriteFaz 2/3
- Stanford Cancer Institute Palo Alto, Palo Alto · 5 mi lwen
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Ap rekriteFaz 2
- Stanford Cancer Institute Palo Alto, Palo Alto · 5 mi lwen
- VA Palo Alto Health Care System, Palo Alto · 5 mi lwen
A Study of PHST001 in Advanced Solid Tumors
Ap rekriteFaz 1
- Stanford University School of Medicine, Palo Alto · 5 mi lwen
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Ap rekriteEtid obsèvasyon
- Stanford University, Palo Alto · 5 mi lwen
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ap rekriteFaz 3
- Stanford Women's Cancer Center, Palo Alto · 5 mi lwen
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Ap rekriteFaz 1
- Stanford University Medical Center, Stanford · 5 mi lwen
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- Stanford Cancer Institute, Stanford · 5 mi lwen
Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors
Ap rekriteFaz 1
- Stanford University, Palo Alto · 5 mi lwen
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Ap rekriteFaz 1
- Stanford, Palo Alto · 5 mi lwen
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Ap rekriteFaz 3
- Palo Alto Medical Foundation-Camino Division, Mountain View
- Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View
- Palo Alto Medical Foundation Health Care, Palo Alto · 5 mi lwen
- ak 1 plis
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Ap rekriteFaz 2
- 150, Palo Alto · 5 mi lwen
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Ap rekriteFaz 3
- Palo Alto Medical Foundation, Palo Alto · 5 mi lwen
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- Stanford University, Stanford · 5 mi lwen
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Ap rekriteFaz 1/2
- Stanford Women's Cancer Center, Palo Alto · 5 mi lwen
Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
Ap rekriteEtid obsèvasyon
- Stanford University School of Medicine, Stanford · 5 mi lwen
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Ap rekriteFaz 1/2
- Stanford Cancer Institute, Stanford · 5 mi lwen
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Ap rekriteFaz 3
- Stanford Ambulatory Surgery Center Lane Operating Room, Palo Alto · 5 mi lwen
- Stanford Women's Cancer Center, Palo Alto · 5 mi lwen
- Stanford Hospital, Palo Alto · 5 mi lwen
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Ap rekriteFaz 2
- Stanford Cancer Center, Palo Alto · 5 mi lwen
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Stanford · 5 mi lwen
Etid Kansè ovè nan lòt vil
- Houston, TX89 etid
- New York City, NY69 etid
- Boston, MA61 etid
- Los Angeles, CA50 etid
- Nashville, TN49 etid
- Arlington, VA46 etid
- Philadelphia, PA44 etid
- Columbus, OH39 etid
- St. Louis, MO38 etid
- Chicago, IL36 etid
- San Antonio, TX31 etid
- Cleveland, OH30 etid
Lòt etid nan Mountain View
- Kansè (tout kalite)40 etid
- Kansè nan tete26 etid
- Kansè Metastatik25 etid
- Kansè Poumon ki pa ti selil21 etid
- Leksemi mieloïd egi19 etid
- Twoub Spektòm Otis17 etid
- Kansè poumon17 etid
- Kansè pwostat15 etid
- Ensifizyans kadyak15 etid
- Otis13 etid
- Leksemi limfoblastik egi13 etid
- Kansè kolorektal13 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.